Ettinger David S
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21213-1000, USA.
Oncologist. 2006 Apr;11(4):358-73. doi: 10.1634/theoncologist.11-4-358.
Dysregulation of the epidermal growth factor receptor (EGFR) signaling pathway is associated with the development and progression of malignancy, and EGFR-targeted therapies offer the promise of better treatment for many types of solid tumors, including non-small cell lung cancer. Anti-EGFR agents include monoclonal antibodies (mAbs) targeting the EGFR extracellular receptor domain and small-molecule tyrosine kinase inhibitors (TKIs) targeting the EGFR intracellular kinase domain. Both mAbs and TKIs have demonstrated encouraging results as monotherapies and in combination with chemotherapy and radiotherapy. This review provides a critical update on the status of these novel therapeutics.
表皮生长因子受体（EGFR）信号通路的失调与恶性肿瘤的发生和发展相关，而针对EGFR的疗法为包括非小细胞肺癌在内的多种实体瘤带来了更好治疗的希望。抗EGFR药物包括靶向EGFR细胞外受体结构域的单克隆抗体（mAb）和靶向EGFR细胞内激酶结构域的小分子酪氨酸激酶抑制剂（TKI）。mAb和TKI作为单一疗法以及与化疗和放疗联合使用均已显示出令人鼓舞的结果。本综述对这些新型疗法的现状进行了重要更新。
